Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 13Active not recruiting 9Completed 4Terminated 3Not yet recruiting 2Withdrawn 1Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasm Metastasis 3Oropharyngeal Neoplasms 2Lymphoma, Follicular 2Glioblastoma 2Colorectal Neoplasms 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Lymphoma 1Lung Neoplasms 1Locally Recurrent Skin Squamous Cell Carcinoma 1HTLV-I Infections 1Eyelid Squamous Cell Carcinoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Carcinoma 1Breast Neoplasms 1Breast Carcinoma In Situ 1Astrocytoma 1Anatomic Stage III Breast Cancer AJCC v8 1Adenocarcinoma of Lung 1

Interventions

romidepsin 1olaparib 1durvalumab 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Urinary Bladder Neoplasms × Magnetic Resonance Spectroscopy × Clear all
NCT03375307 2026-06-05

Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes

National Cancer Institute (NCI)

Phase 2 Suspended
60 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡